Assessment of DBS technology for the detection of therapeutic antibodies

DBS 技术检测治疗性抗体的评估

阅读:20
作者:Peter J Prince, Katherine C Matsuda, Mw Retter, G Scott

Background

Quantitating levels of therapeutic proteins in serum or plasma is critical for determining exposure levels and establishing pharmacokinetic parameters. Traditionally, whole blood is not used, mostly due to its inability to be frozen and potential issues with assay interference. To investigate the ability to reproducibly quantitate therapeutic antibodies present in dried blood spots (DBS) compared with a typical serum sample-based method, we used ELISA and electrochemiluminescence immunoassays to measure therapeutic drug levels present in DBS samples.

Conclusions

DBS are a viable alternative to the use of conventional serum or plasma samples for quantitative therapeutic antibody measures.

Results

Measurements of antibody therapeutics in DBS were reproducible, yielding methods that are precise, accurate and met expected sensitivity requirements compared with plasma-based methods. Conclusions: DBS are a viable alternative to the use of conventional serum or plasma samples for quantitative therapeutic antibody measures.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。